Transdermal hormone therapy and bone health

Area of Science:

• Reproductive Endocrinology
• Bone Metabolism
• Menopause Management

Background:

• The Women's Health Initiative (WHI) findings in 2002 led to a significant decline in hormone therapy (HT) use among menopausal women.
• Discontinuation of HT resulted in increased vasomotor symptoms, vaginal atrophy, and a recognized higher risk of osteoporosis due to decreased estradiol levels.
• While bisphosphonates reduce fracture risk in osteoporotic women, they are ineffective in non-osteoporotic women.

Purpose of the Study:

• To evaluate the impact of non-oral hormone therapy regimens on bone mineral density and fracture risk in menopausal women.
• To assess the efficacy of non-oral HT in mitigating osteoporosis risk, particularly in light of reduced oral HT use.

Main Methods:

• Review of existing clinical studies and data on non-oral hormone therapy use in menopausal women.
• Analysis of bone mineral density and fracture risk data associated with various non-oral HT regimens.

Main Results:

• Numerous studies consistently demonstrate that non-oral hormone regimens positively impact bone mineral density, maintaining or increasing it in users.
• This effect on bone mineral density was observed even with estrogen doses considered too low to alleviate other menopausal symptoms.
• Oral estrogen remains the only HT proven to reduce fracture risk in both osteoporotic and non-osteoporotic women.

Conclusions:

• Non-oral hormone therapies appear to have a beneficial effect on bone mineral density in menopausal women.
• Further research is warranted to directly assess the fracture risk reduction capabilities of non-oral HT regimens.
• Non-oral HT may offer a viable alternative for managing bone health in menopausal women, complementing symptom relief.